AI's impact in drug discovery is coming fast, predicts GSK's Hal Barron

Biotech is famously skeptical of Silicon Valley pitches to fix all that ails drug discovery with a prescription for pairing big data and artificial intelligence.

But one of the pharma industry's top R&D chiefs anticipates the day is coming fast when advanced computing techniques like machine learning yield results for the sector.